Key result
Streptokinase therapy for acute MI can trigger delayed serum sickness regardless of dose or route.
Why the study?
Serum sickness after streptokinase therapy in acute myocardial infarction may occur independently of dose or administration route and can complicate treatment.
Comparison
Early high dose intravenous streptokinase
Design
Case report
Authors
Loading...
Serum sickness may occur after streptokinase independent of dose or route; leaves open incidence and relevance for intracoronary use.
Serum sickness can occur as a complication of streptokinase therapy for acute myocardial infarction, regardless of dose or route of administration.
Alexopoulos et al. (1984) studied this question. Streptokinase therapy for acute myocardial infarction can be complicated by delayed serum sickness, which may occur independently of the dose or route of administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: